According to a 2014 study by British researchers, people who are trying to quit smoking are nearly 60 percent more likely to succeed with electronic cigarettes such as Evolv than with nicotine patches or gum. The study was published in the Addiction journal on May 21, 2014.
The study noted that despite containing nicotine, e-cigarettes contain no tobacco smoke, reducing the withdrawal symptoms and cravings induced by normal cigarettes. The DNA 200, which is Evolv's patented power regulation digital switch-mode DC-DC converter for personal vaporizers, allows smokers to customize and monitor their experiences by using its EScribe software.
The Ohio-based manufacturer was the first, in 2010, to introduce a variable wattage e-cigarette in a market that was dominated by variable voltage-based personal vaporizers.